NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats

Neuropharmacology
R H WessellJ D Oh

Abstract

Sensitization of NMDA receptors containing the NR2B subunit has been increasingly associated with various forms of synaptic plasticity, including those implicated in the pathogenesis of extrapyramidal motor dysfunction. To determine whether activation of NR2B containing receptors contributes to the development and maintenance of levodopa-induced response changes in parkinsonian animals, we evaluated the effects of the selective NR2B antagonist CP-101,606 on these response alterations in unilateral 6-hydroxydopamine (6-OHDA) lesioned rats. Three weeks of twice-daily levodopa treatment decreased the duration of the rotational response to acute levodopa challenge. The response alteration was associated with an increase in GluR1 (S831) phosphorylation in medium spiny neurons of the dorsolateral striatum. Both the attenuated rotational response and augmented GluR1 phosphorylation were decreased by CP-101,606 treatment. These CP-101,606 effects were observed when the compound was administered either at the end of chronic levodopa treatment (ameliorative effect) or together with the twice-daily levodopa treatment for 3 weeks (preventive effect). Furthermore, concurrent administration of CP-101,606 with levodopa potentiated the ability...Continue Reading

References

May 1, 1994·The Journal of Comparative Neurology·D G StandaertJ B Penney
Oct 1, 1995·Neuropharmacology·H Mori, M Mishina
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetT N Chase
Jul 20, 1999·European Journal of Biochemistry·C CortiE Carafoli
Oct 29, 2000·Trends in Neurosciences·T N Chase, J D Oh
Nov 30, 2000·The Journal of Biological Chemistry·T R SoderlingD Brickey
Apr 4, 2001·The European Journal of Neuroscience·D CentonzeP Calabresi
May 10, 2001·Hippocampus·A M Kleschevnikov, A Routtenberg
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·P Del DottoU Bonuccelli
May 7, 2002·Neurobiology of Learning and Memory·Justin Shobe
Jul 12, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Joanne E Nash, Jonathan M Brotchie
Jul 2, 2003·Neurotoxicity Research·Thomas N ChaseJustin D Oh

❮ Previous
Next ❯

Citations

Jan 24, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jesse E HansonQiang Zhou
Feb 22, 2012·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Antonio Sanz-ClementeKatherine W Roche
Sep 21, 2006·Clinical Pharmacokinetics·Timothy J TaylorMegan A Gibbs
Feb 22, 2014·Journal of Neural Transmission·Clare Finlay, Susan Duty
Mar 20, 2008·Expert Opinion on Therapeutic Targets·Jon Stoessl
Dec 3, 2008·Expert Opinion on Emerging Drugs·Karl Strecker, Johannes Schwarz
May 11, 2005·Expert Opinion on Investigational Drugs·Spiros Konitsiotis
May 24, 2011·Molecular and Cellular Neurosciences·Clare M Gladding, Lynn A Raymond
Nov 5, 2015·Bioorganic & Medicinal Chemistry Letters·Sandeep GawaskarBernhard Wünsch
Jul 12, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Jonathan M Brotchie
Feb 19, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Antonio PisaniPaolo Calabresi
Jul 15, 2009·British Journal of Pharmacology·Laetitia MonyPierre Paoletti
Sep 11, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Paolo CalabresiBarbara Picconi
Sep 2, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·John G NuttJaren W Landen
Jul 13, 2006·European Journal of Pharmacology·Fabrizio Gardoni, Monica Di Luca
Jul 26, 2015·Progress in Neurobiology·Matthieu F BastideErwan Bézard
Jul 23, 2014·The International Journal of Neuroscience·Janneth GonzalezGeorge E Barreto
Nov 19, 2008·Parkinsonism & Related Disorders·Eleni Koutsilieri, Peter Riederer
Jul 23, 2013·European Journal of Pharmacology·Manuela Mellone, Fabrizio Gardoni
Dec 3, 2014·Bioorganic & Medicinal Chemistry·Sandeep GawaskarBernhard Wünsch
Dec 3, 2014·Current Opinion in Pharmacology·Fabrizio Gardoni, Monica Di Luca
Dec 25, 2010·Brain : a Journal of Neurology·Barbara PicconiPaolo Calabresi
Feb 2, 2018·Journal of Neural Transmission·Manuela Mellone, Fabrizio Gardoni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.